Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TOFACITINIB CITRATE

TOFACITINIB CITRATE

Standard Dose
22MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview TOFACITINIB CITRATE is listed in Drugs@FDA under application 218668 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient TOFACITINIB CITRATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 22MG Sponsor DEXCEL Submission history Latest submission status date: 2024-12-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview TOFACITINIB CITRATE is listed in Drugs@FDA under application 218668 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient TOFACITINIB CITRATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 22MG Sponsor DEXCEL Submission history Latest submission status date: 2024-12-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
TOFACITINIB CITRATE (TOFACITINIB CITRATE) | Drug Monograph | MedicHelpline